Siltuximab
- Generic Name
- Siltuximab
- Brand Names
- Sylvant
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 541502-14-1
- Unique Ingredient Identifier
- T4H8FMA7IM
- Background
Siltuximab is a chimeric (human-mouse) monoclonal immunoglobulin G1-kappa antibody produced in a Chinese hamster ovary (CHO) cell line by recombinant DNA technology. Siltuximab prevents the binding of IL-6 to soluble and membrane-bound IL-6 receptors by forming high affinity complexes with human interleukin-6 (IL-6). Its use is indicated for the treatment of...
- Indication
Siltuximab is indicated for the treatment of patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative. Siltuximab did not bind to virally produced IL-6 in a nonclinical study and was therefore not studied in patients with MCD who are HIV or HHV-8 positive.
- Associated Conditions
- Castleman Disease
- Associated Therapies
- -
A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC)
- Conditions
- Interventions
- First Posted Date
- 2006-10-11
- Last Posted Date
- 2014-08-20
- Lead Sponsor
- Centocor, Inc.
- Target Recruit Count
- 106
- Registration Number
- NCT00385827
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.